CD177 and psoriasis: Psoriasis patients who received etanercept (a soluble TNF receptor that prevents TNFα-mediated responses by competitively inhibiting the interaction of TNF with cell-surface receptors) exhibited a significant improvement in fatigue and depression, the former correlated with and the latter not correlated with objective measures (skin clearance or joint pain) [69].